Precision BioSciences Inc
PBS0
Company Profile
Business description
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Contact
302 East Pettigrew Street
Dibrell Building, Suite A-100
DurhamNC27701
USAT: +1 919 314-5512
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
67
Stocks News & Analysis
stocks
Investment decisions in overvalued bank drive strong results
Shares fall despite a broadly unchanged outlook.
stocks
Overvalued ASX share hurt by normalising conditions
Investors overly optimisitc about future prospects.
stocks
After earnings, is Amazon stock a buy, a sell, or fairly valued?
With temperature on tariffs easing and a raised fair value estimate, here’s what we think of Amazon’s results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,097.50 | 40.60 | 0.45% |
| CAC 40 | 7,950.18 | 14.59 | -0.18% |
| DAX 40 | 23,569.96 | 164.06 | -0.69% |
| Dow JONES (US) | 46,987.10 | 74.80 | 0.16% |
| FTSE 100 | 9,682.57 | 53.21 | -0.55% |
| HKSE | 26,398.20 | 156.37 | 0.60% |
| NASDAQ | 23,004.54 | 49.46 | -0.21% |
| Nikkei 225 | 50,760.50 | 484.13 | 0.96% |
| NZX 50 Index | 13,579.86 | 19.35 | -0.14% |
| S&P 500 | 6,728.80 | 8.48 | 0.13% |
| S&P/ASX 200 | 8,823.20 | 31.40 | 0.36% |
| SSE Composite Index | 3,996.26 | 1.29 | -0.03% |